Pharmaceuticals

After its stock mysteriously surged over 2,000% intraday, China Pharma announced a $5M offering at a steep discount. A strategic move or a sign of strain?

Acclaimed scientist Michael Ehlers leaves big pharma's orbit for an AI startup. It's more than a career move; it's a test of whether technology can fix our broken drug development system.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.

With a proven record in biosimilars, new President Dominic Bégin is set to deepen Organon's impact on women's health and healthcare affordability in Canada.

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

While debates over UN dues persist, American companies quietly secured over $2 billion in UN contracts, turning global initiatives into a major revenue stream.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

A $15.97M federal grant will help Virginia's APM Tech Hub create a fully domestic drug supply chain, tackling critical shortages and boosting US manufacturing.

A high-level Dubai summit unites tech, pharma, and policy to combat the GCC's escalating IBD crisis, heralding a new era of AI-driven care and IL-23 therapies.

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

As Qlosi refill rates hit 49%, Orasis shuns telehealth trends, investing in programs that put eye care professionals back at the center of care.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

A new partnership promises to solve digital health's fragmentation problem, linking therapy access with AI-driven adherence to create a new benchmark for value.

Verrica Pharma's deal with Medomie brings YCANTH®, a novel skin treatment, to Israel, highlighting a strategy that blends global growth with public health.

PolyPid inks a transformative partnership with Azurity for its surgical infection drug, D-PLEX100, securing over $320M and a clear path to market.

Jupiter Neurosciences' $100M deal for a novel MDMA drug signals a major strategic shift, betting on a new era of psychedelic medicine in the U.S.

A new Virginia pharmacy isn't just local expansion. It's a look at the high-tech, high-touch future of elder care and a strategic play in a growing market.